Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Richman

Showing results (271-280 of 307) with videos related to

Pageof 31
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2003
Enhanced therapeutic index of radioimmunotherapy (RIT) in prostate cancer patients: comparison of radiation dosimetry for 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA)-peptide versus 2IT-DOTA monoclonal antibody linkage for RITSally J DeNardo, Gerald L DeNardo, A Yuan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 1999
Dosimetry-based therapy in metastatic breast cancer patients using 90Y monoclonal antibody 170H.82 with autologous stem cell support and cyclosporin AC M Richman, S J DeNardo, R T O'Donnell, et al.
Anticancer Research|May 1, 1997
Radioimmunotherapy for advanced breast cancer using I-131-ChL6 antibodyS J Denardo, L F O'Grady, C M Richman, et al.
Thyroid : Official Journal of the American Thyroid Association|July 13, 2019
Differences in Thyroid Nodule Cytology and Malignancy Risk Between Children and AdultsChristine E Cherella, Trevor E Angell, Danielle M Richman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2001
Radioimmunotherapy with (111)In/(90)Y-2IT-BAD-m170 for metastatic prostate cancerR T O'Donnell, S J DeNardo, A Yuan, et al.
The Journal of Clinical Endocrinology and Metabolism|April 19, 2022
Thyroid Nodule Shape Independently Predicts Risk of MalignancyTheodora Pappa, Sara Ahmadi, Athanasios Bikas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2005
High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human anti-mouse antibodyCarol M Richman, Sally J Denardo, Robert T O'Donnell, et al.
Abdominal Radiology (New York)|June 29, 2018
Reader agreement and accuracy of ultrasound features for hepatic steatosisCheng William Hong, Austin Marsh, Tanya Wolfson, et al.
Cancer Research|July 25, 2025
Carbonic Anhydrase Inhibition Sensitizes Group 3 Medulloblastoma to Radiation TherapyCory M Richman, Alexandra Rasnitsyn, Borja L Holgado, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 12, 2013
Outcomes of allogeneic hematopoietic cell transplantation in patients with dyskeratosis congenitaShahinaz M Gadalla, Carmem Sales-Bonfim, Jeanette Carreras, et al.
Pageof 31

Showing results (271-280 of 307) with videos related to

Sort By:
Pageof 31
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2003
Enhanced therapeutic index of radioimmunotherapy (RIT) in prostate cancer patients: comparison of radiation dosimetry for 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA)-peptide versus 2IT-DOTA monoclonal antibody linkage for RITSally J DeNardo, Gerald L DeNardo, A Yuan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 1999
Dosimetry-based therapy in metastatic breast cancer patients using 90Y monoclonal antibody 170H.82 with autologous stem cell support and cyclosporin AC M Richman, S J DeNardo, R T O'Donnell, et al.
Anticancer Research|May 1, 1997
Radioimmunotherapy for advanced breast cancer using I-131-ChL6 antibodyS J Denardo, L F O'Grady, C M Richman, et al.
Thyroid : Official Journal of the American Thyroid Association|July 13, 2019
Differences in Thyroid Nodule Cytology and Malignancy Risk Between Children and AdultsChristine E Cherella, Trevor E Angell, Danielle M Richman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2001
Radioimmunotherapy with (111)In/(90)Y-2IT-BAD-m170 for metastatic prostate cancerR T O'Donnell, S J DeNardo, A Yuan, et al.
The Journal of Clinical Endocrinology and Metabolism|April 19, 2022
Thyroid Nodule Shape Independently Predicts Risk of MalignancyTheodora Pappa, Sara Ahmadi, Athanasios Bikas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2005
High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human anti-mouse antibodyCarol M Richman, Sally J Denardo, Robert T O'Donnell, et al.
Abdominal Radiology (New York)|June 29, 2018
Reader agreement and accuracy of ultrasound features for hepatic steatosisCheng William Hong, Austin Marsh, Tanya Wolfson, et al.
Cancer Research|July 25, 2025
Carbonic Anhydrase Inhibition Sensitizes Group 3 Medulloblastoma to Radiation TherapyCory M Richman, Alexandra Rasnitsyn, Borja L Holgado, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 12, 2013
Outcomes of allogeneic hematopoietic cell transplantation in patients with dyskeratosis congenitaShahinaz M Gadalla, Carmem Sales-Bonfim, Jeanette Carreras, et al.
Pageof 31